Mavupharma

Developing orally bioavailable, non-nucleotide modulators of the STING pathway to treat cancer and infectious diseases

Mavupharma is a drug discovery and development company focused on novel approaches to selectively targeting the STING (stimulator of interferon genes) pathway, leveraging the innate immune system to treat cancer and infectious diseases. The company was founded by Frazier, and its leadership team includes Frazier Senior Advisor Mike Gallatin and Frazier EIRs Bob Baltera and Brian Farmer.

Year of Investment

2016

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Seattle, Washington